Randomized Controlled Trial of Acupuncture in the Treatment of Diminished ovarian reserve with Insomnia

注册号:

Registration number:

ITMCTR2025001081

最近更新日期:

Date of Last Refreshed on:

2025-05-29

注册时间:

Date of Registration:

2025-05-29

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刺治疗卵巢储备功能减退伴失眠的随机对照试验

Public title:

Randomized Controlled Trial of Acupuncture in the Treatment of Diminished ovarian reserve with Insomnia

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刺治疗卵巢储备功能减退合并失眠的随机对照试验

Scientific title:

Randomized Controlled Trial of Acupuncture in the Treatment of Diminished ovarian reserve with Insomnia

研究课题的正式科学名称简写:

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘瓅莹

研究负责人:

杨洁

Applicant:

Liu LiYing

Study leader:

Yang Jie

申请注册联系人电话:

Applicant telephone:

+86 186 2811 5041

研究负责人电话:

Study leader's telephone:

+86 138 8229 6714

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

767000032@qq.com

研究负责人电子邮件:

Study leader's E-mail:

jenny_yang_jie@126.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

四川省成都市金牛区十二桥路37号

研究负责人通讯地址:

四川省成都市金牛区十二桥路37号

Applicant address:

37 shierqiao road Jinniu District Chengdu SichuanChinese Medicine

Study leader's address:

37 shierqiao road Jinniu District Chengdu SichuanChinese Medicine

申请注册联系人邮政编码:

Applicant postcode:

610032

研究负责人邮政编码:

Study leader's postcode:

610032

申请人所在单位:

成都中医药大学

Applicant's institution:

Chengdu University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)生殖伦理委员会伦审第(39)号

伦理委员会批件附件:

Approved file of Ethical Committee:

View

批准本研究的伦理委员会名称:

四川锦欣西囡妇女儿童医院生殖医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Sichuan Jinxin Sinan Women's and Children's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024/11/27 0:00:00

伦理委员会联系人:

刘敬

Contact Name of the ethic committee:

Liu Jing

伦理委员会联系地址:

四川省锦江区毕昇路66号

Contact Address of the ethic committee:

66 Bisheng Road Jinjiang District Sichuan Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 28 6550 6841

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1776774965@qq.com

研究实施负责(组长)单位:

四川锦欣西囡妇女儿童医院

Primary sponsor:

Sichuan Jinxin Xinan Women and Children's Hospital

研究实施负责(组长)单位地址:

四川省锦江区毕昇路66号

Primary sponsor's address:

66 Bisheng Road Jinjiang District Sichuan Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川省

市(区县):

成都

Country:

People's Republic of China

Province:

Si Chuan province

City:

Chengdu

单位(医院):

四川锦欣西囡妇女儿童医院

具体地址:

四川省锦江区毕昇路66号

Institution
hospital:

Sichuan Jinxin Xinan Women and Children's Hospital

Address:

66 Bisheng Road Jinjiang District Sichuan Province

经费或物资来源:

国家自然科学基金面上项目(82174517)

Source(s) of funding:

National Natural Science Foundation of China (82174517)

研究疾病:

卵巢储备功能减退

研究疾病代码:

Target disease:

Diminished ovarian reserve(DOR)

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

其它

Others

研究目的:

探讨真针刺对比假针刺治疗卵巢储备功能减退(Diminished ovarian reserve,DOR)伴失眠患者的疗效差异变化以寻找针刺治疗DOR伴失眠的治疗靶点。

Objectives of Study:

To explore the differences in therapeutic effects between true acupuncture and sham acupuncture in treating patients with diminished ovarian reserve (DOR) accompanied by insomnia so as to find the therapeutic targets of acupuncture treatment for DOR with insomnia.

药物成份或治疗方案详述:

Description for medicine or protocol of treatment in detail:

纳入标准:

(1)20岁≤年龄<45岁; (2)满足DOR诊断标准; (3)月经周期规律,即(28±7)天; (4)符合《国际睡眠障碍分类第三版》(ICSD - 3)慢性失眠的诊断标准,且匹兹堡睡眠质量指数(Pittsburgh sleep quality index,PSQI)评分>7分; (5)入组前1个月内未使用镇静催眠类药物,且近3个月内未接受过针灸治疗; (6)未参加其他正在进行的临床研究; (7)患者本人签署或由其直系亲属代签知情同意书。 注:同时符合以上7条的受试者可纳入本研究。

Inclusion criteria

(1) Age is between 20-45 years old; (2) Meeting the diagnostic criteria for DOR; (3) Regular menstrual cycle (28±7) days; (4) Meeting the diagnostic criteria for chronic insomnia in the International Classification of Sleep Disorders Third Edition (ICSD-3) and having a Pittsburgh Sleep Quality Index (PSQI) score greater than 7 points; (5) Not having used sedative-hypnotic drugs within 1 month before enrollment and not having received acupuncture treatment within the past 3 months; (6) Not participating in other ongoing clinical studies; (7) The patient himself/herself signs the informed consent form or it is signed on behalf of the patient by his/her direct relative. Note: Subjects who meet all the above 7 criteria can be included in this study.

排除标准:

(1)合并有高血压、糖尿病、冠心病、癫痫、严重心脑血管、肝、肾、恶性肿瘤、造血等系统性疾病者; (2) 患有其他类型的睡眠障碍,包括睡眠呼吸暂停综合征、睡眠相关运动障碍、中枢性睡眠障碍、嗜睡症、不宁腿综合征等; (3)存在酒精或其他药物滥用或依赖者; (4)沟通和认知障碍,或患有双向情感障碍、焦虑症、精神分裂症、人格改变等精神疾病者; (5)有出血倾向以及容易发生感染者,或患有严重过敏性疾病、或皮肤有溃疡、瘢痕等禁止针刺的患者; (6)正在参加其他临床试验者。 注:凡符合上述任何一条的患者,即予以排除。

Exclusion criteria:

(1) Those with comorbid systemic diseases such as hypertension diabetes mellitus coronary heart disease epilepsy severe cardiovascular and cerebrovascular diseases liver diseases kidney diseases malignant tumors hematopoietic diseases etc.; (2) Those suffering from other types of sleep disorders including sleep apnea syndrome sleep-related movement disorders central sleep disorders narcolepsy restless legs syndrome etc.; (3) Those with alcohol or other drug abuse or dependence; (4) Those with communication and cognitive disorders or suffering from mental diseases such as bipolar disorder anxiety disorder schizophrenia personality change etc.; (5) Patients with a bleeding tendency and those prone to infections or those with severe allergic diseases or those with skin ulcers scars and other conditions that prohibit acupuncture; (6) Those currently participating in other clinical trials. Note: Any patient who meets any of the above criteria will be excluded.

研究实施时间:

Study execute time:

From 2025-06-15

To      2026-06-15

征募观察对象时间:

Recruiting time:

From 2025-06-15

To      2026-06-15

干预措施:

Interventions:

组别:

真针刺组

样本量:

64

Group:

true acupuncture group

Sample size:

干预措施:

针刺治疗

干预措施代码:

Intervention:

true acupuncture

Intervention code:

组别:

假针刺组

样本量:

64

Group:

sham acupuncture group

Sample size:

干预措施:

假针治疗

干预措施代码:

Intervention:

sham acupuncture

Intervention code:

样本总量 Total sample size : 128

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

四川省

市(区县):

成都市

Country:

People's Republic of China

Province:

Si Chuan

City:

Chengdu

单位(医院):

四川锦欣西囡妇女儿童医院

单位级别:

三甲

Institution/hospital:

Sichuan Jinxin Xinan Women and Children's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

弗林德斯疲劳量表评分

指标类型:

次要指标

Outcome:

Flinders Fatigue Scale Score

Type:

Secondary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline, treatment 4 weeks, treatment 8 weeks, treatment 12 weeks, follow-up 4 weeks, follow-up 8 weeks

Measure method:

指标中文名:

抗苗勒管激素

指标类型:

次要指标

Outcome:

Anti-mullerian hormone

Type:

Secondary indicator

测量时间点:

基线、治疗12周(月经第2-5天)

测量方法:

Measure time point of outcome:

Baseline, treatment 12 weeks (2-5 days of menstruation)

Measure method:

指标中文名:

状态-特质焦虑量表评分

指标类型:

次要指标

Outcome:

state-trait anxiety inventory Score

Type:

Secondary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline, treatment 4 weeks, treatment 8 weeks, treatment 12 weeks, follow-up 4 weeks, follow-up 8 weeks

Measure method:

指标中文名:

贝克抑郁量表评分

指标类型:

次要指标

Outcome:

the Beck Depression Inventory Score

Type:

Secondary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline, treatment 4 weeks, treatment 8 weeks, treatment 12 weeks, follow-up 4 weeks, follow-up 8 weeks

Measure method:

指标中文名:

日间嗜睡量表评分

指标类型:

次要指标

Outcome:

Epworth Sleepiness Scale Score

Type:

Secondary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline treatment 4 weeks treatment 8 weeks treatment 12 weeks follow-up 4 weeks follow-up 8 weeks

Measure method:

指标中文名:

匹兹堡睡眠质量指数量表评分

指标类型:

主要指标

Outcome:

Pittsburgh Sleep Quality Index Score

Type:

Primary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline treatment 4 weeks treatment 8 weeks treatment 12 weeks follow-up 4 weeks follow-up 8 weeks

Measure method:

指标中文名:

失眠严重程度量表评分

指标类型:

次要指标

Outcome:

Insomnia Severity Index Score

Type:

Secondary indicator

测量时间点:

基线、治疗4周、治疗8周、治疗12周、随访4周、随访8周

测量方法:

Measure time point of outcome:

Baseline treatment 4 weeks treatment 8 weeks treatment 12 weeks follow-up 4 weeks follow-up 8 weeks

Measure method:

指标中文名:

血清性激素水平

指标类型:

次要指标

Outcome:

Serum sex hormone levels

Type:

Secondary indicator

测量时间点:

基线、治疗12周(月经第2-5天)

测量方法:

Measure time point of outcome:

Baseline, treatment 12 weeks (2-5 days of menstruation)

Measure method:

指标中文名:

经阴道B超检查

指标类型:

次要指标

Outcome:

Transvaginal B-ultrasonography

Type:

Secondary indicator

测量时间点:

基线、治疗12周(月经第2-5天)

测量方法:

Measure time point of outcome:

Baseline, treatment 12 weeks (2-5 days of menstruation)

Measure method:

指标中文名:

清晨型-夜晚型问卷评分

指标类型:

次要指标

Outcome:

morningnsee-evening ness questionnaire Score

Type:

Secondary indicator

测量时间点:

基线、治疗12周

测量方法:

Measure time point of outcome:

Baseline, treatment 12 weeks

Measure method:

指标中文名:

慕尼黑睡眠时型问卷评分

指标类型:

次要指标

Outcome:

Munich chronotype questionnaire Score

Type:

Secondary indicator

测量时间点:

基线、治疗12周

测量方法:

Measure time point of outcome:

Baseline, treatment 12 weeks

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

标本中文名:

大便

组织:

Sample Name:

Stool

Tissue:

人体标本去向

使用后销毁

说明

Fate of sample 

Destruction after use

Note:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 20
Min age years
最大 45
Max age years

Recruiting status:

Participant age:

性别:

Gender:

女性

Female

随机方法(请说明由何人用什么方法产生随机序列):

通过随机数字表法进行随机化分组。由研究者和评价者之外的第三人编制和保管随机分配卡,严格做好分配隐藏,受试者按纳入试验的先后顺序,依次拆开相应的随机信封,将受试者随机分为:真针刺组或假针刺组,并严格按照分组执行操作。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method for randomization grouping. A third person other than the researcher and evaluator will compile and keep the random allocation card and strictly hide the allocation. The subjects will open the corresponding random envelopes according to the order of inclusion in the experiment and the subjects will be randomly divided into real acupuncture group or fake acupuncture group and the operation will be strictly carried out according to the group

盲法:

单盲。对受试者施盲,并且严格实施研究者、操作者、统计者三分离。

Blinding:

Single blinding. Subjects were blinded and strict separation of investigator operator and statistician was enforced..

是否共享原始数据:

IPD sharing:

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

No

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病历记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

ITMCTR BJ-ICP:07032215-5 Tip: IE8 is recommended Use the system with widescreen display resolution above